Onconetix, Inc.
For the period ended Dec 31, 2024. Filed Jun 2, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Jun 2, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Onconetix, Inc. | ||
| Date: May 30, 2025 | By: | /s/ Karina Fedasz |
|---|---|---|
| Karina Fedasz | ||
| Interim Chief Executive Officer and Interim Chief Financial Officer | ||
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities indicated on May 30, 2025.
| Signature | Title |
|---|---|
| /s/ Karina Fedasz | Interim Chief Executive Officer and Interim Chief Financial Officer |
| Karina Fedasz | |
| /s/ Andrew Oakley | Non-Executive Chairman of the Board |
| Andrew Oakley | |
| /s/ Thomas Meier | Director |
| Thomas Meier | |
| /s/ Timothy Ramdeen | Director |
| Timothy Ramdeen | |
| /s/ Ajit Singh | Director |
| Ajit Singh | |
| /s/ Simon Tarsh | Director |
| Simon Tarsh | |
Our common stock is traded on The Nasdaq Capital Market under the trading symbol “ONCO.”
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.